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EGF  Endothelial growth factor
FXIIIa  Activated subunit A of blood coagulation 
factor XIII
GTP  Guanosine triphosphate
GTPγS  Guanosine 5′-O-[gamma-thio]triphosphate
IC50  Inhibitor concentration resulting in 50 % 
inhibition
Kd  Dissociation constant
LC–MS/MS  Liquid chromatography–tandem mass 
spectrometry
PBS  Phosphate buffered saline
PET  Positron emission tomography
PH  Pulmonary hypertension
SAR  Structure-activity relationship
TG2  Transglutaminase type 2
Introduction
Positron emission tomography is a non-invasive imaging 
technique that allows for quantitative imaging of biological 
processes (Phelps 2000; Czernin and Phelps 2002; Berg-
ström et al. 2003; Jones and Rabiner 2012). PET depends 
on the incorporation of unstable β+ emitting nuclides, i.e., 
nuclides with a neutron deficiency, into biologically rel-
evant molecules. After emission, these positively charged 
particles, so-called positrons, having a mass equal to that 
of electrons will collide with electrons in tissue, thereby 
losing their kinetic energy. Ultimately, a positron will com-
bine with a nearby electron after which the two particles 
will annihilate, resulting in the emission of two 511 keV 
photons travelling in opposite direction due to the conser-
vation of angular momentum. Co-incidence detection of 
these two photons by detectors (often positioned in a cir-
cular detector ring), identifies the line of response along 
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as celiac disease, cancer, and fibrotic and neurodegenera-
tive diseases. In parallel with becoming an attractive target 
for therapy, interest in the development of compounds for 
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which the annihilation took place. Subsequent processing 
of a large number of such co-incidence events ultimately 
leads to a three-dimensional map, reflecting the original 
distribution of the injected radiotracer (Fig. 1). Biologically 
relevant molecules, in which positron emitting nuclides can 
be incorporated, include small organic compounds, such 
as enzyme inhibitors or substrates, receptor agonists or 
antagonist, and peptides and biologicals, such as monoclo-
nal antibodies and fragments (Miller et al. 2008; van Don-
gen et al. 2007). The obtained radiopharmaceutical or PET 
tracer is applied in molecular imaging with PET.
The radiochemistry that is applied to synthesize the PET 
tracers differs drastically from the traditional organic chem-
istry in that high sub-stoichiomectric amounts of radioac-
tive reagent, typically in the nanomole range, are reacted 
with micromolar amounts of the other reagents. The large 
excess of reagents relative to the small amount of radioac-
tive reagent allows for rapid reactions, compatible with the 
short radionuclide half-lives. Furthermore, the small scale 
of the reactions enables rapid purification by means of pre-
parative HPLC. PET tracers are typically obtained in ster-
ile and isotonic injectable solutions and are administered 
intravenously, allowing for rapid distribution throughout 
the subject. As a result of the nanomole amounts of tracer 
compound administered, no biological effects are antici-
pated, making PET a purely analytical diagnostic imag-
ing modality (Miller et al. 2008). Moreover, PET is a fast 
and quantitative molecular imaging technique allowing for 
dynamic molecular imaging and assessment of parameters, 
such as Bmax, Kd, and receptor occupancy, amongst others 
(Bergström et al. 2003).
For PET imaging using small organic molecules, car-
bon-11 and fluorine-18 are commonly the nuclides of 
choice (Miller et al. 2008). Their physical half-lives of 20.3 
and 110.8 min are compatible with the in vivo kinetics of 
such small molecules. Radiosynthesis of these radiotrac-
ers is limited by their short half-lives, resulting in limited 
synthetic toolboxes compared with those in the tradi-
tional organic chemistry. Therefore, not all compounds 
are amenable for radiosynthesis and analogues of those 
lead compounds may be necessary. In general, monoclo-
nal antibodies do allow for radiolabelling, for example, by 
modification of lysine residues with a radiometal chelating 
moiety (Vosjan et al. 2010). Due to their slower kinetics, 
usually longer lived radionuclides, such as Cu-64, Zr-89, 
and I-124, are used (van Dongen et al. 2007).
The choice of biologically active compounds for radi-
olabelling usually is driven by several factors, the location 
of the biological target being dominant in this selection. 
Targets located intracellularly or in the central nervous sys-
tem can only be reached via passive diffusion using small 
non-polar organic compounds (Pike 2009), whereas extra-
cellular or membrane bound peripheral targets can also 
be reached using bulkier molecules, such as peptides and 
antibodies. Furthermore, lead compounds are generally 
selected based on affinity, selectivity, and metabolic sta-
bility (Pike 2009). As PET only measures the distribution 
of radioactivity and not the chemical form, it is important 
to carefully study metabolism of a putative radioligand 
(Pike 2009). At present, the in vivo kinetics of existing 
TG2 inhibitors which are largely unknown and metabolism 
data, if available, is largely depending on in vitro plasma or 
hepatocyte stability data (Wityak et al. 2012; Prime et al. 
2012a, b; Badarau et al. 2015). This limited availability 
of stability data hampers selection of high-potential com-
pounds for translation to PET agents. Radiolabelling of a 
TG2 inhibitor, however, allows for following its distribu-
tion as well as its metabolic stability (Van der Wildt et al. 
2016). Furthermore, because of increased sensitivity of 
LC–MS/MS, formed metabolites may be chemically char-
acterized ex vivo (Ma et al. 2010).
Transglutaminases comprise a class of structurally 
related enzymes containing eight catalytically active fam-
ily members, named TG1–TG7 and FXIII (Griffin et al. 
2002). These enzymes are well known for their ability of 
cross-linking proteins by forming an intermolecular isopep-
tide bond, more specifically an epsilon-(gamma-glutamyl)
lysine bond, between the side chains of a glutamine resi-
due as an acyl-donor substrate and a lysine residue of an 
acyl-acceptor substrate. These isopeptide bonds are highly 
stable towards proteolysis and introduce mechanical sta-
bility in tissues (Griffin et al. 2002). Transglutaminase 
type 2, TG2, plays an important role during apoptosis by 
intracellular cross-linking of cellular components, thereby 
Fig. 1  Basic principles of PET. A PET nuclide, incorporated in a bio-
logically relevant molecule, decays and emits a positron inside a sub-
jects’ brain. Following annihilation with a nearby electron (depicted 
as e−), two 511 keV photons are formed, which travel in opposite 
directions and are detected simultaneously by two opposing (in co-
incidence) detector elements within the PET detector ring. Combin-
ing co-incidence counts from all detector pairs allows for recon-
struction of the quantitative distribution of the radioactive ligand in 
three-dimensional space
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preventing excessive leakage of cellular debris and sub-
sequent inflammatory responses during cell death (Fésüs 
and Szondy 2005). Extracellularly, TG2 is believed to cre-
ate a stable environment by forming metabolically stable 
crosslinks between various matrix proteins (Zemskov et al. 
2006). Independent of its cross-linking activity, however, 
TG2 forms ternary complexes with integrins and fibronec-
tin, resulting in intracellular activation of various processes, 
thereby assisting in assisting in cell adhesion and migra-
tion (Akimov et al. 2000). TG2 cross-linking activity is 
tightly regulated via various mechanisms. First, TG2 can 
adapt two distinct conformations (Fig. 2) (Liu et al. 2002; 
Pinkas et al. 2007). The closed conformation, based on two 
C-terminal β-barrel domains being tightly folded over the 
catalytic core domain, does not display cross-linking activ-
ity. In this conformation, however, TG2 is known to act 
as a G-protein involved in signalling processes (Im et al. 
1997). The open conformation, where the two β-barrels 
shift to an upright position parallel to the core and N-ter-
minal domain, results in exposure of the active-site cysteine 
residue, allowing cross-linking to occur. The latter con-
formation is induced by high calcium and low GTP/GDP 
concentrations, whereas the opposite conditions favour the 
closed conformation. Therefore, it is anticipated that, under 
physiological conditions, intracellular TG2 has low cross-
linking activity, whereas extracellularly, the high calcium 
and low GTP/GDP concentrations allow TG2 mediated 
cross-linking. In addition, TG2 cross-linking activity is reg-
ulated by the redox state of the enzyme, as a disulfide bond 
between cysteine 370 and cysteine 371 induces cross-link-
ing inactivation of TG2 (Stamnaes et al. 2010). In addition, 
by forming ternary protein complexes with integrins and 
fibronectin, as well as by nitrosylation (Santhanam et al. 
2010), TG2 cross-linking activity might be limited (Siegel 
et al. 2008). Local increases in cross-linking activity of 
TG2 in vivo may be induced by various molecular stimuli, 
including retinoids, EGF, and sphingophospholipids (Singh 
et al. 2001; Antonyak et al. 2009; Lai et al. 1997).
Aberrant TG2 expression and/or activity are increas-
ingly associated with the pathogenesis of a number of dis-
orders, e.g., autoimmune diseases, fibrotic diseases, can-
cer, and diseases of the central nervous system (Siegel and 
Khosla 2007). In addition, it has been identified as a target 
for therapeutic intervention (Pietsch et al. 2013). Presum-
ably best understood is the role of TG2 in celiac disease, 
where open conformation TG2 mediates the deamidation of 
dietary gluten peptides via a gluten peptide-TG2 thioester 
intermediate, resulting in T-cell activation and inflamma-
tory processes (Klöck et al. 2012). In kidney, liver and lung 
fibrotic diseases, TG2 is suspected to increasingly crosslink 
extracellular matrix proteins, directly producing scar tissue 
(Grenard et al. 2001; Johnson et al. 1997; Olsen et al. 2011). 
Fig. 2  Potential strategies for TG2 PET imaging. a Closed confor-
mation TG2 can be targeted by either radiolabelled antibodies or GTP 
site binding molecules; b open conformation TG2 can be targeted 
by radiolabelled irreversible inhibitors, TG2 antibodies, reversible 
inhibitors, or acyl-donor substrates; c intermediate thioester between 
acyl-donor substrate and TG2 that can be intercepted by radiolabelled 
nucleophiles, such as amines
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In oncology, the role of TG2 is more ambiguous, with either 
protective anti-apoptotic and pro-apoptotic functions being 
described (Kotsakis and Griffin 2007). TG2 upregulation has 
been associated with increased metastasis of various tumour 
cell lines (Mehta et al. 2004; Satpathy et al. 2007) and drug 
resistance (Kumar et al. 2010) by promoting epithelial-to-
mesenchymal transition, independent of cross-linking activ-
ity. In addition, upregulation of the pro-survival transcrip-
tion factor NF-κB may play a role in drug resistance (Brown 
2013), by TG2-mediated cross-linking and deactivation of 
NF-κB’s endogenous inhibitor IκBα. The TG2 cross-linking 
dependency remains questionable (Brown 2013). In neuro-
degenerative diseases, TG2 cross-linking of well-known dis-
ease specific proteins, such as amyloid β, huntingtin, and tau, 
has been associated with the formation of stable neurotoxic 
aggregates (Wilhelmus et al. 2008).
However, because of its presence in multiple cellu-
lar compartments as well as outside the cell (Slife et al. 
1985; Lesort et al. 1998), its multiple conformations (Liu 
et al. 2002; Pinkas et al. 2007), and functions (Gundemir 
et al. 2012), intrinsically TG2 is a difficult protein to study 
in vivo. The development of PET tracers for imaging of 
TG2 activity in vivo may lead to a better understanding of 
the role of this interesting protein in disease. This review 
illustrates the potential strategies for TG2 PET imaging 
and describes potent lead compounds within the context of 
potential translation to TG2 PET tracers.
General
This review will focus on compounds with high potential 
that justify further elaboration and compounds from dif-
ferent compound classes that allow for different imaging 
strategies (Figs. 2, 3). As the acyl transfer mechanism of 
TG2 follows a double displacement reaction (Keillor et al. 
2014), various enzymatic states may be intercepted with 
a PET imaging agent (Fig. 2). In the closed conformation 
(Fig. 2a), TG2 may be targeted by antibodies or by small 
organic molecules at the GTP-binding domain. Besides 
targeting with antibodies, the open conformation (Fig. 2b) 
may bind to radiolabelled reversible and irreversible TG2 
inhibitors, as well as acyl-donor substrates. Finally, the 
intermediate thioester between TG2 and the acyl-donor 
may be intercepted by radiolabelled acyl-acceptor sub-
strates (Fig. 2c). Chemical structures of small molecule 
compounds described in this review are depicted in Fig. 3.
Irreversible inhibitors
The majority of previously proposed potent TG2 inhibi-
tors are irreversible inhibitors, with recurring moieties, 
such as diazoketones, α-haloketones, dialkylsulfonium 
salts, 3-halo-4,5-dihydroxyisoxazoles, and acryl amides 
or related Michael acceptors (Keillor et al. 2015). The 
use of PET labelled irreversible TG2 inhibitors should, 
provided that the newly formed covalent bond is, indeed, 
irreversible, lead to accumulation of the radiotracer in 
regions with high-local TG2 cross-linking activity. The 
first radiolabelled irreversible transglutaminase inhibitor 
(Freund et al. 1994) was based on the class of imidazole 
derivatives. By designing two carbon-14 (not a PET iso-
tope) labelled regioisomers of the non-selective inhibitor 
1,3-dimethyl-2[(2-oxopropyl)thio]imidazolium chloride 
(NTU283 in Fig. 3), the mechanism of transglutaminase 
inhibition was confirmed as active-site cysteine acetonyla-
tion, with the imidazole moiety as leaving group (Freund 
et al. 1994). Therefore, straightforward carbon-11 meth-
ylation on the imidazole moiety of a desmethyl precursor 
would result in labelling of the leaving imidazole group 
which would not be retained in tissue, but rather be cleared 
from the original reaction site. Carbon-11 labelling of the 
acetonyl functionality is not feasible using the currently 
available radiochemical toolbox. Analogues of this inhibi-
tor bearing a fluorine-18 atom on the acetonyl group might 
be developed. NTU283, however, suffers from low potency 
and comparable affinity towards the transglutaminase FXI-
IIa (Griffin et al. 2008; Freund et al. 1994).
More potent and selective irreversible TG2 inhibitors 
carrying an acrylamide moiety have recently been reported 
(1–3 in Fig. 3) (Prime et al. 2012a, b; Wityak et al. 2012). 
Conveniently, carbon-11 radiosynthesis of acryl amides 
has been reported using various strategies resulting in the 
carbon-11 atom at the acrylamide carbonyl position, ren-
dering this class of Michael acceptor inhibitors amenable 
to radiolabelling (Eriksson et al. 2007). The most conveni-
ent amongst these synthetic strategies is the palladium-
mediated one-pot [11C]CO aminocarbonylation method. In 
fact, recently, the carbon-11 radiosynthesis together with 
the evaluation of three potent irreversible TG2 inhibitors 
radiolabelled using this methodology was described (Van 
der Wildt et al. 2016). In healthy rodents, however, these 
compounds displayed low metabolic stability at tracer 
concentrations, with biological half-lives below 45 min. 
After selecting the most stable of these three compounds, 
i.e., compound [11C]3 (Fig. 3), autoradiography experi-
ments on MDA-MB-231 tumour sections, known for its 
high expression of TG2 (Mehta et al. 2004), demonstrated 
selective and specific binding to TG2 (Van der Wildt et al. 
2016). Nevertheless, TG2-targeting potential of this com-
pound in vivo still remains to be established. Other potent 
acrylamide inhibitors based on an aminopiperidine core 
have been reported. Apart from [11C]CO aminocarbonyla-
tion, the strongest inhibitor within this class, compound 
9q, potentially allows for radiolabelling at the methoxy 
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position by straightforward [11C]MeI methylation of the 
corresponding O-desmethyl precursor (Prime et al. 2012b). 
Recently, Badarau et al. also reported on the development 
of potent TG2 inhibitors carrying the acrylamide moi-
ety (Badarau et al. 2015). Unfortunately, the most potent 
compound 3h, which is the strongest irreversible inhibitor 
reported to date, showed low microsomal stability. Com-
pound 3h, however, did show potency in vivo in a hyper-
tensive nephropathy model, using local administration of 
3h by constant infusion. As for compound 9q, carbon-11 
Fig. 3  Radiolabelled TG2 inhibitors, substrates, and other compounds that may be suited as lead compounds for the development of TG2 PET 
imaging agents and as such are discussed in this review. The position of the carbon-11 label in compound [11C]1–[11C]3 is depicted with asterisk
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radiolabelling of 3h might be performed by aminocarbon-
ylation or N-methylation of the N-desmethyl precursor. 
Zedira GmbH has reported the start of Phase I trials using 
their compound ZED1227, a promising peptidomimetic 
irreversible inhibitor carrying a Michael acceptor other than 
acrylamide [Zedira GmbH patent filing WO2014012858 
(A1), 2014]. This compound is accessible for carbon-11 
methylation at either of two methyl groups.
Z006 (Z-DON-Val-Pro-Leu-OMe) is a highly potent and 
selective peptidic inhibitor of TG2 (Verhaar et al. 2011; 
Schaertl et al. 2010). Theoretically, Z006 allows for radi-
olabelling at the C-terminal methyl ester employing either 
[11C]MeI or [11C]CH2N2. Methylesters, however, are not 
very stable in vivo, and, therefore, are rarely the preferred 
site of introduction of the PET label. Recently, radiosyn-
thesis and preliminary in vivo evaluation of fluorine-18 
labelled analogues of Z006 have been reported ([18F]tTG-
036 and [18F]tTG-038 in Fig. 3) (Van der Wildt et al. 2013, 
2015). As expected, the methyl ester on [18F]tTG-038 
appeared to be metabolically unstable in vivo. Interest-
ingly, however, the resulting carboxylic acid was demon-
strated to be metabolically stable and an active TG2 inhibi-
tor as well. Together, these results merit further evaluation 
of [18F]tTG-038 in vivo. ERW1041E (DiRaimondo et al. 
2013) was shown to prevent BAP incorporation in a pul-
monary hypertension mouse model following intraperi-
toneal administration. This work concludes that a longi-
tudinal TG2 activity study in PH patients is warranted to 
confirm TG2 as a biomarker for this disease, emphasizing 
the necessity for a TG2 PET tracer. To allow radiolabelling, 
equipotent analogues of ERW1041E that are accessible for 
fluorine-18 labelling were designed as putative future TG2 
PET tracers (ERW1041E analogue 2a in Fig. 3). Although 
ERW1041E has shown in vivo inhibition of TG2 activity 
in this mouse model at 50 mg kg−1, it still remains to be 
elucidated whether this compound class will prove valu-
able at tracer concentrations. Furthermore, in the previous 
research, analogues of ERW1041E were not able to inhibit 
TG2 cross-linking activity in an intestinal inflammation 
model despite various ways of inhibitor administration 
(Siegel et al. 2008).
Reversible active-site inhibitors
Binding potential, which reflects Bmax/Kd, is a key predic-
tor of the potency of a reversible radiopharmaceutical for 
imaging a given target [Eckelman and Mathis 2006]. High-
affinity compounds are thus preferred, especially if target 
expression is low. Because little is known about Bmax for 
TG2 in physiological and diseased states, high-affinity 
compounds should be selected as starting point for PET 
tracer development. To date, in contrast to irreversible 
TG2 inhibitors, only few reversible inhibitors with IC50′s 
in the two digit nanomolar range have been reported. Fol-
lowing screening of an existing drug library, the Janus 
kinase inhibitor ZM39923 and its ‘metabolite’ ZM449829 
(Brown et al. 2000; Lai et al. 2008) were reported as potent 
TG2 inhibitors with 10 and 5 nM IC50′s, respectively. 
Carbon-11 labelling of ZM39923 should be feasible by 
a reductive amination reaction between amine precursor 
and [11C]acetone (Berridge et al. 1992) or by alkylation 
of the corresponding precursor with [11C]benzyl iodide 
(Pekošak et al. 2015). Including 10 mM DTT in the incu-
bation solution, however, resulted in a drastic increase in 
IC50 to micromolar values for both inhibitors (Lai et al. 
2008). These IC50 values corresponded with those reported 
in a later study (Schaertl et al. 2010). Although the pro-
vided explanation for this phenomenon included, besides 
an ‘unknown complex mechanism of inhibition’ involve-
ment of these inhibitors in promoting disulfide bonds and 
thus inactivating the enzyme (Lai et al. 2008), it appears 
more likely that ZM39923 is converted to the actual TG2 
inhibitor ZM449829 by a retro Michael reaction (Brown 
et al. 2000). Using similar assay conditions, i.e., PBS solu-
tion, rapid conversion of ZM39923 to ZM449829 has 
already been observed. This newly formed Michael accep-
tor compound ZM449829, in turn, is responsible for irre-
versible TG2 inhibition. The subsequent cross-reactivity 
of ZM449829 towards DTT, as a thiol competing with the 
active-site cysteine residue, results in a loss of TG2 inhi-
bition. Radiolabelling of ZM449829 could be achieved on 
the carbonyl position by a Suzuki or Stille [11C]CO inser-
tion reaction (Nader and Oberdorfer 2002). However, the 
putative cross-reactivity with various thiols will likely 
limit the chance of successful in vivo TG2 imaging using 
either [11C]ZM39923 or [11C]ZM449829. Ozaki et al. also 
reported on β-aminoketone structures, such as ZM39923, 
as potent active-site TG2 inhibitors (Ozaki et al. 2010). 
Their most promising compound 1 (Fig. 3) allows for car-
bon-11 radiolabelling at the tert-butyl (Elsinga et al. 1995) 
or, like ZM39923, at the benzyl functionality (Pekošak 
et al. 2015). It is conceivable, however, that Ozaki com-
pound 1 also acts as a prodrug that via retro Michael reac-
tion converts to an active inhibitor, given the structural sim-
ilarities to ZM39923. No stability data for the developed 
compounds were provided, nor selectivity data towards 
other transglutaminases or biological reactive thiols (e.g., 
glutathione, caspase). In addition, no DTT was used in 
their assay. Together, it is possible that their reversible 
inhibitors are actually prodrugs for non-selective irrevers-
ible TG2 inhibitors (Ozaki et al. 2010) following a similar 
mechanism as for compound ZM449829. Another class of 
reported reversible inhibitors is the cinnamoyl-based inhibi-
tors, such as CP4d (Fig. 3) (Pardin et al. 2008a, b). Potency 
of these compounds, however, is limited, hampering their 
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use as lead compound for PET tracer development (Fig. 3, 
reported IC50: 2.1 µM; Ki: 174 nM). In addition to the low 
affinity, although being reported as a reversible inhibitor 
competitive with the acyl-donor substrate, this compound 
class could potentially react as irreversible inhibitors. The 
thiol-reactive Michael acceptor motif is present in the cin-
namoyl structure (Esterbauer et al. 1975) and has been 
shown in related structures to react with biologically active 
thiols, as present in transglutaminases (Schwöbel et al. 
2010). The selectivity data of these compounds towards 
transglutaminase FXIIIa and cysteineprotease caspase 
3, although seemingly promising, are biased by the pres-
ence of DTT in these counter assays (Pardin et al. 2008a). 
DTT, omitted in the TG2 inhibition assay, could very well 
be acting as a competitive nucleophile for cinnamoyl-based 
inhibitors and thus preventing FXIIIa and caspase 3 inhibi-
tion, suggesting selectivity. The putative irreversible inhi-
bition of these compounds is further encouraged by the 
fact that modifications at the α,β-unsaturated ketone motif, 
losing the Michael acceptor reactivity, results in complete 
loss of potency (Pardin et al. 2008a). Finally, a recent study 
discussing the reactivity between biological thiols and cin-
namoyl-coumarin constructs showed that cinnamoyl com-
pounds with the highest Michael acceptor reactivity carried 
a p-nitrophenyl group, conjugated to the α,β-unsaturated 
ketone, a structure that is sharing high structural similari-
ties with structure CP4d (Aliaga et al. 2014). Therefore, it 
is highly desirable to evaluate the stability of the inhibitors 
mentioned above in the presence of thiols and to perform 
TG2 inhibition experiments in the presence of competing 
thiols (DTT). These experiments might result in re-evalua-
tion of the exact binding mode of this class of compounds 
(Pardin et al. 2009).
In summary, it seems that at present, no reversible 
active-site inhibitors for TG2 with low nanomolar affinities 
are available. Furthermore, cross-reactivity of irreversible 
inhibitors, although, perhaps, also for reversible inhibitors, 
towards thiols (e.g. glutathione, DTT) should be carefully 
determined prior to starting elaborate SAR studies to avoid 
false positive in vitro inhibition results.
GTP-binding site inhibitors
Orthosteric GTP-binding site inhibitors of TG2 as well as 
inhibitors with unknown binding sites that inhibit GTP-
binding have been described (Lai et al. 1998; Duval et al. 
2005). Other than GTP itself or closely related analogues, 
such as dGTP-, GTPγS-, or Bopdipy-modified GTPγS 
(Datta et al. 2006), no structurally distinct orthosteric inhib-
itors have been reported, suggesting the GTP-binding site 
to be highly specialized in this particular binding (Schaertl 
et al. 2010). In addition, the fact that GTP-binding domains 
are present in all G-proteins likely discards the GTP-bind-
ing site as suitable target for PET radiotracer development, 
as selectivity issues will arise. In contrast, it has been sug-
gested that the class of hydrazine inhibitors prevents TG2 
cross-linking activity by binding allosterically to the GTP-
binding site and to multiple enzyme conformers (Duval 
et al. 2005; Case and Stein 2007; Schaertl et al. 2010). 
However, due to slow-binding kinetics, sub-optimal affin-
ity, and unknown binding mechanism, PET tracer develop-
ment based on this hydrazine scaffold appears not to be an 
attractive strategy.
Acyl-acceptor substrates
Carbon-14 radiolabelled acyl-acceptor substrates have 
been at the heart of transglutaminase discovery in the late 
1950s, when it was found that liver-derived protein extracts 
were responsible for amine incorporation into proteins 
(Sarkar et al. 1957). An important advantage of labelled 
substrates over inhibitors is the potential signal magnifica-
tion by means of catabolic trapping, as multiple substrates 
per transglutaminase enzyme can be incorporated into the 
local tissue, whereas inhibitors can maximally bind at a 1:1 
ratio with the transglutaminase enzyme. Acyl-acceptor sub-
strates for TG2 differ from acyl-donor substrates or active-
site inhibitors in that they do not bind to the enzyme itself, 
but rather compete with naturally present amines, or water, 
for interception of the intermediate thioester between 
enzyme and acyl-donor substrate. In contrast to the first 
step in the cross-linking reaction, the nucleophilic attack on 
the thioester is not selective (Keillor et al. 2014). In addi-
tion, processing of amines in vivo is not limited to TG2, 
as other transglutaminases as well as other enzymes have 
amines as substrates. Together, the lack of selectivity of 
acyl-acceptor substrates will likely hamper the success of 
this approach towards TG2 PET imaging agents. Nonethe-
less, TG2-mediated incorporation of the substrate BAP was 
demonstrated ex vivo in lung tissue using a mouse model 
of hypoxia-induced pulmonary hypertension (DiRaimondo 
et al. 2013). In such an ex vivo approach, selectivity data 
are obtained by pre-treatment of test animals with a TG2 
inhibitor after which the free amine substrate is removed 
by thoroughly washing the tissue sections. In the case of 
in vivo PET imaging, removal of free ligand by sequential 
washing procedures is impossible, potentially resulting in 
a much lower specific signal. Nevertheless, two research 
groups have reported preliminary results on the fluorine-18 
labelling of polyamines, such as putresceine, spermidine, 
or cadaverine using [18F]SFB as amine reactive prosthetic 
group (Wodtke et al. 2013; Ackermann et al. 2014). In a 
small pilot experiment using SK-RC-52 tumour bear-
ing mice, a high tumour to blood activity ratio of [18F]
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fluorobenzamide-cadaverine was obtained (Ackermann 
et al. 2014). Whether this signal was TG2 mediated, how-
ever, remains to be elucidated, but it is likely that more 
in vivo imaging results will be published in the near future.
Acyl-donor substrates
Although various TG2 specific acyl-donor substrates have 
been developed for measuring TG2 activity in vitro (Pietsch 
et al. 2013), to the best of our knowledge, no reports have 
described ex vivo or in vivo use of radiolabelled acyl-donor 
substrates for measuring TG2 cross-linking activity. One 
report has described the radiosynthesis of a fluorine-18 
labelled acyl-donor substrate (Vaidyanathan et al. 2009). 
This fluorine-18 labelled TG2 specific substrate T32 was 
selected based on a phage-displayed peptide library screen-
ing (Sugimura et al. 2006). Unfortunately, the desired TG2 
substrate, [18F]14 was obtained with poor purity and was 
not formulated in a solution ready for injection. As a con-
sequence, no in vivo work has been reported with this sub-
strate. TG2-reactive peptide sequences should in vivo be 
incorporated in tissues with a high-local TG2 activity with 
the same potential signal magnification as described for 
acyl-acceptor substrates (vide supra). Such peptidic con-
structs often allow for N-terminal modification to enable 
chemoselective reaction with a fluorine-18 building block 
or with a chelating moiety for incorporation of a radiometal 
of choice. Using a comparable approach, FXIIIa activity 
imaging has been attempted using 99mTc- and 111In-labelled 
peptidic α2-antiplasmin regions, which were functioning 
as acyl-donor substrates (Edwards et al. 2006; Nahrendorf 
et al. 2006). The 99mTc labelled construct showed high 
uptake in vitro in plasma clots and moderate uptake in vivo 
in rodent blood clots, which was determined ex vivo by 
means of a biodistribution experiment. Ex vivo, after thor-
ough washing of the tissues, the 111In-labelled construct 
was shown to be selectively incorporated by FXIIIa in the 
infarct region in a mouse model of myocardial infarction. 
Unfortunately, no in vivo imaging was performed in either 
study. However, it seems likely that a similar strategy, when 
carefully selecting and developing a high-affinity peptide 
for TG2, could be used for imaging of extracellular TG2 
activity in vivo.
Antibodies
PET imaging using radiolabelled antibodies, a technique 
commonly referred to as ‘Immuno-PET’ (Van Dongen et al. 
2015), has shown to be well suited for imaging of extracel-
lular targets, such as receptors, and other membrane bound 
proteins, such as enzymes and transporters. Furthermore, 
compared to small organic molecules, antibodies gener-
ally display less uptake in liver and kidneys and thus allow 
for PET imaging studies concerning pathologies of these 
specific organs (Grenard et al. 2001; Johnson et al. 1997). 
Since TG2 has two highly distinct conformations, the char-
acteristics of the radiolabelled antibody, more precisely. the 
epitope to which the antibody is directed, will determine 
what will be measured. When interested in measuring TG2 
expression, independent of conformation, the antibody 
might best be raised against any TG2 domain, though one 
must consider that extracellularly, the N-terminal domain 
is likely bound to fibronectin (Hang et al. 2005) and the 
C-terminal domain involved in integrin binding (Akimov 
et al. 2000), potentially hampering antibody accessibil-
ity. For measuring extracellular TG2 activity rather than 
expression, the specific antibody should be designed to 
bind selectively to the open conformation. It must be noted 
that this is the assumed extracellular conformation due 
to the mM calcium concentrations in the interstitial fluid 
(Király et al. 2009). As such, the core domain, including 
the catalytic cross-linking site, is likely the preferred tar-
geted epitope, as this region is only accessible in the cata-
lytically active open conformation. A TG2 transamidation 
inhibiting antibody D11D12 has been reported, (patent 
filing WO2013175229, 2013; Wang et al. 2013), although 
it has not been reported whether this antibody selectively 
binds to the open conformation. This TG2 antibody showed 
inhibition of TG2 transamidation-mediated angiogenesis 
and wound healing in cellular models (Wang et al., 2013) 
and further development might result in a huge step towards 
TG2 transamidation inhibition therapies. Furthermore, the 
well-known TG2 antibody CUB7402, amongst others, has 
shown TG2-inhibiting properties by preventing adhesion 
of Swiss 3T3 fibroblasts (Verderio et al. 1998), although 
CUB7402 TG2 transamidation inhibiting properties were 
lost when TG2 was preincubated with Ca2+ (Esposito et al. 
2002), suggesting that CUB7402 does not bind to the open 
conformation of TG2, but to TG2 in a closed conformation. 
It is anticipated that ‘TG2 Immuno-PET’ will be a valuable 
tool in future research to increase understanding on TG2 
biology.
Future perspectives
With several research groups reporting novel TG2 PET 
tracers in publications, conference abstracts, and annual 
reports, we are without any doubt at the frontier of in vivo 
TG2 PET imaging (Van der Wildt et al. 2013, 2015, 2016; 
Ackermann et al. 2014; Vaidyanathan et al. 2009), and 
there is no doubt that results from in vivo TG2 PET imag-
ing studies in animal models of TG2 overexpression/over-
activity will appear soon. Furthermore, highly potent small 
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molecule inhibitors are continuously being developed at 
multiple academic and industrial institutes, increasing the 
options on lead compound selection for PET radiochem-
ists (Keillor et al. 2015). Table 1 depicts the advantages 
and disadvantages of potential strategies for TG2 PET radi-
otracer development.
At present, the use of irreversible TG2 inhibitors appears 
to be an attractive strategy. In particular, irreversible acryla-
mide inhibitors readily allow for radiolabelling with car-
bon-11 and can thus be readily evaluated in vivo (Eriksson 
et al. 2007; Van der Wildt et al. 2016). Labelled acyl-donor 
substrates, successfully applied for ex vivo measurements 
of FXIIIa activity (Nahrendorf et al. 2006; Edwards et al. 
2006), could also be applicable for imaging of TG2 cross-
linking activity. Furthermore, TG2-inhibiting antibodies 
have been developed that might, unlike small molecules, 
allow for TG2 imaging in kidney and liver pathologies 
(Wang et al. 2013). Whether the radiolabelled antibody will 
reflect local open, closed, or both conformations of TG2 
will fully depend on the antibody characteristics. Taken 
together, it is anticipated that PET will play an important 
role in moving in vitro and ex vivo biology findings on 
TG2 into mammalian in vivo studies. As such, it could play 
a pivotal role in monitoring of target engagement in TG2 
drug development.
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